Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.4K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.4K
Vapor Pressure Lowering03:28

Vapor Pressure Lowering

31.0K
The equilibrium vapor pressure of a liquid is the pressure exerted by its gaseous phase when vaporization and condensation are occurring at equal rates:
31.0K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.4K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.4K
Subviral Agents01:29

Subviral Agents

556
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
556
Air-entraining Agents01:27

Air-entraining Agents

270
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
270
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.

BMJ open·2026
Same author

Obicetrapib and renal function: A welcome signal, but not yet a kidney story.

American journal of preventive cardiology·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Familial Hypercholesterolemia in Women: Diagnosis, Treatment, and Cardiovascular Outcomes Across the Lifespan.

Current atherosclerosis reports·2026
Same author

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

European heart journal·2026
Same author

CETP Inhibitors: Back With a New Target.

Circulation research·2026
Same journal

Mitochondrial STING Governs Glycolytic Reprogramming in Diabetic Cardiomyopathy.

Circulation research·2026
Same journal

Hypoxia-Induced Epas1-Myl9/12 Axis Shapes the Pathology of Pulmonary Hypertension.

Circulation research·2026
Same journal

Proteogenomics of Hypertrophic Cardiomyopathy Reveals Subtype-Specific Therapy.

Circulation research·2026
Same journal

Impaired Endothelial Cell Cholesterol Metabolism Promotes Vascular Inflammation in Sleep Apnea.

Circulation research·2026
Same journal

Engineered Heart Tissues Facilitate Noncoding Variant Studies in Cardiomyopathy.

Circulation research·2026
Same journal

NUAK1 Inhibition Alleviates Ischemia-Reperfusion Injury via SYNE1-YAP1.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Cholesterol-Lowering Agents.

Savvas Hadjiphilippou1, Kausik K Ray1

  • 1From the Department of Primary Care and Public Health, Imperial College, London, United Kingdom.

Circulation Research
|February 1, 2019
PubMed
Summary
This summary is machine-generated.

Lowering low-density lipoprotein cholesterol (LDL-C) with statins reduces cardiovascular disease (CVD) risk. This review examines whether treating all individuals, even those at low risk, is beneficial for shifting the overall CVD risk distribution.

Keywords:
cardiovascular diseasecholesterolprimary preventionrisk factorssecondary prevention

More Related Videos

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.6K
Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
11:07

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans

Published on: December 19, 2014

13.1K

Related Experiment Videos

Last Updated: Jan 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.6K
Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
11:07

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans

Published on: December 19, 2014

13.1K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Lipidology

Background:

  • Cardiovascular disease (CVD) is the leading global cause of mortality.
  • Low-density lipoprotein cholesterol (LDL-C) is a primary causal factor in atherosclerotic CVD.
  • Statin therapy is the current standard for lipid-lowering and CVD risk reduction.

Purpose of the Study:

  • To review the established role of statin therapy in CVD prevention.
  • To discuss the limitations of current risk prediction models.
  • To explore the potential benefits and drawbacks of treating broader populations to shift the LDL-C risk distribution.

Main Methods:

  • Literature review of studies on statin efficacy and CVD risk.
  • Analysis of risk prediction tools and their accuracy.
  • Discussion of the log-linear relationship between LDL-C reduction and CVD risk reduction.

Main Results:

  • Statin therapy effectively reduces LDL-C and cardiovascular risk, particularly in secondary prevention and genetic dyslipidemias.
  • Most cardiovascular events occur in individuals at moderate to low risk, who are often undertreated.
  • Current risk prediction tools may not identify individuals with high lifelong risk but low short-term risk.

Conclusions:

  • The effectiveness of statins in reducing LDL-C and CVD risk is well-established.
  • A key clinical question is whether to broaden statin treatment to shift the entire population's LDL-C risk distribution.
  • This review presents arguments for and against universal or wider LDL-C lowering strategies.